30 research outputs found
Antiangiogenic potential of an anthraquinone metabolite isolated from a marine fungus.
This is a communication in the format of a posterThe potential of marine organisms to yield bioactive molecules is vast and largely unexplored. Significantly, certain bioactive compounds derived from the marine environment have already received approval as anticancer drugs1. Among the multitude of bioactive compounds found in marine organisms, anthraquinones represent a notable class of molecules, with over 200 structurally related compounds having been isolated from diverse species of marine fungi2. Danthron (1,8-dihydroxy-9,10-anthraquinone) serves as an exemplary member of anthraquinones, possessing anti-tumoral and anti-angiogenic properties that have yet to be fully elucidated. Therefore, the primary objective of this study was to comprehensively investigate and understand these specific properties.Funding: Funding: Projects PID2019-105010RB-I00 (Ministry of Science and Innovation, Government of Spain), UMA18-FEDERJA-220 and P20_00257 (Junta de Andalucía-FEDER)
The assistance to the congress has an help from the Plan Propio de Investigación (UMA). Universidad de Málaga. Campus de Excelencia Internacional Andalucía Tech
Antioxidant potential of an anthraquinone metabolite isolated from a marine fungus.
Marine ecosystem is a fruitful source of many pharmacologically active. In particular, a number of marine anthraquinones and their derivatives, have been studied for their potential as anticancer and antimetastatic
agents, although little is known about their antiangiogenic activities. In addition, there is some controversy regarding the poor antioxidant effect of these marine secondary metabolites. In this study, we describe for the first time the antiangiogenic activity of an anthraquinone, isolated from a marine fungus, which was evidenced in vitro by the inhibition of the activated endothelial cells survival, proliferation, and differentiation into tubelike structures. Furthermore, we have demonstrated its protective effect against reactive oxygen species (ROS), especially in presence of hydrogen peroxide, a potent prooxidant agent. These results were evidenced by a reduced ROS production and an increased redox capacity of cells after treatment with this anthraquinone, evidenced through the staining with DCFHDA and the sulfhydryl groups determination, respectively. The observation that this compound appears to present a more potent effect in tumor than in endothelial cells, suggests a putative selectivity. All these results highlight the need for further study of this molecule as a potential therapeutic agent for cancer and other angiogenesisdependent diseases.Universidad de Málaga. Campus de Excelencia Internacional Andalucía Tech
Influence of the Main Design Factors on the Optimal Fuel Cell-Based Powertrain Sizing
The design of the optimal power distribution system (PDS or powertrain) for fuel cell-based vehicles is a complex task due to PDS comprising one or more power converters, several types of secondary energy sources, a fuel cell, several control loops, and protections, among others. The optimized powertrain design tries to minimize the mass, volume, and cost, and also to improve system efficiency, fuel economy (both hydrogen and electricity), and vehicle autonomy. This paper analyzes the influence of four different factors that deeply affect the optimal powertrain design, in particular: the minimum power delivered by the fuel cell, the storage of the recovered energy from the regenerative braking periods, the battery technology, and the maximum battery state-of-charge variation. The analysis of these factors is carried out over a set of 9 different fuel cell-based architectures applied to a light vehicle, and a 10th architecture corresponding to a pure electric vehicle. This analysis provides the knowledge of how these design factors affect the mass, volume, and cost of the optimal power distribution architectures, and how they can be considered in the design.This research was funded by the Spanish Ministry of Economy and Competitiveness and ERDF, grant number DPI2014-53685-C2-1-R
Danthron, an Anthraquinone Isolated from a Marine Fungus, Is a New Inhibitor of Angiogenesis Exhibiting Interesting Antitumor and Antioxidant Properties
The role played by a sustained angiogenesis in cancer and other diseases stimulates the
interest in the search for new antiangiogenic drugs. In this manuscript, we provide evidence that
1,8- dihydroxy-9,10-anthraquinone (danthron), isolated from the fermentation broth of the marine
fungus Chromolaenicola sp. (HL-114-33-R04), is a new inhibitor of angiogenesis. The results obtained
with the in vivo CAM assay indicate that danthron is a potent antiangiogenic compound. In vitro
studies with human umbilical endothelial cells (HUVEC) reveal that this anthraquinone inhibits
certain key functions of activated endothelial cells, including proliferation, proteolytic and invasive
capabilities and tube formation. In vitro studies with human breast carcinoma MDA-MB231 and
fibrosarcoma HT1080 cell lines suggest a moderate antitumor and antimetastatic activity of this
compound. Antioxidant properties of danthron are evidenced by the observation that it reduces the
intracellular reactive oxygen species production and increases the amount of intracellular sulfhydryl
groups in endothelial and tumor cells. These results support a putative role of danthron as a new
antiangiogenic drug with potential application in the treatment and angioprevention of cancer and
other angiogenesis-dependent diseases.Partial funding for open access charge: Universidad de Málag
The synthetic molecule stauprimide impairs cell growth and migration in triple-negative breast cancer
Stauprimide, a semi-synthetic derivative of staurosporine, is known mainly for its potent differentiation-enhancing properties in embryonic stem cells. Here, we studied the effects of stauprimide in cell growth and migration of triple-negative breast cancer cells in vitro, evaluating its potential antitumoral activity in an orthotopic mouse model of breast cancer in vivo. Our results from survival curves, EdU incorporation, cell cycle analysis and annexin-V detection in MDA-MB-231 cells indicated that stauprimide inhibited cell proliferation, arresting cell cycle in G2/M without induction of apoptosis. A decrease in the migratory capability of MDA-MB-231 was also assessed in response to stauprimide. In this work we pointed to a mechanism of action of stauprimide involving the modulation of ERK1/2, Akt and p38 MAPK signalling pathways, and the downregulation of MYC in MDA-MB-231 cells. In addition, orthotopic MDA-MB-231 xenograft and 4T1 syngeneic models suggested an effect of stauprimide in vivo, increasing the necrotic core of tumors and reducing metastasis in lung and liver of mice. Together, our results point to the promising role of stauprimide as a putative therapeutic agent in triple-negative breast cancer.MRI experiments were performed in the ICTS “NANBIOSIS”, more specifically in the U28 Unit at the Andalusian Centre for Nanomedicine & Biotechnology (BIONAND). Cell cultures were performed in the Cell Culture Service at the Central Support Services of Research (SCAI) of the University of Málaga. // Partial funding for open access charge: Universidad de Málaga / CBUA
Canagliflozin and renal outcomes in type 2 diabetes and nephropathy
BACKGROUND Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium–glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. METHODS In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to <90 ml per minute per 1.73 m2 of body-surface area and albuminuria (ratio of albumin [mg] to creatinine [g], >300 to 5000) and were treated with renin–angiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of <15 ml per minute per 1.73 m2), a doubling of the serum creatinine level, or death from renal or cardiovascular causes. Prespecified secondary outcomes were tested hierarchically. RESULTS The trial was stopped early after a planned interim analysis on the recommendation of the data and safety monitoring committee. At that time, 4401 patients had undergone randomization, with a median follow-up of 2.62 years. The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respectively (hazard ratio, 0.70; 95% confidence interval [CI], 0.59 to 0.82; P=0.00001). The relative risk of the renal-specific composite of end-stage kidney disease, a doubling of the creatinine level, or death from renal causes was lower by 34% (hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P<0.001), and the relative risk of end-stage kidney disease was lower by 32% (hazard ratio, 0.68; 95% CI, 0.54 to 0.86; P=0.002). The canagliflozin group also had a lower risk of cardiovascular death, myocardial infarction, or stroke (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P=0.01) and hospitalization for heart failure (hazard ratio, 0.61; 95% CI, 0.47 to 0.80; P<0.001). There were no significant differences in rates of amputation or fracture. CONCLUSIONS In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial
Background: Short-term treatment for people with type 2 diabetes using a low dose of the selective endothelin A receptor antagonist atrasentan reduces albuminuria without causing significant sodium retention. We report the long-term effects of treatment with atrasentan on major renal outcomes. Methods: We did this double-blind, randomised, placebo-controlled trial at 689 sites in 41 countries. We enrolled adults aged 18–85 years with type 2 diabetes, estimated glomerular filtration rate (eGFR)25–75 mL/min per 1·73 m 2 of body surface area, and a urine albumin-to-creatinine ratio (UACR)of 300–5000 mg/g who had received maximum labelled or tolerated renin–angiotensin system inhibition for at least 4 weeks. Participants were given atrasentan 0·75 mg orally daily during an enrichment period before random group assignment. Those with a UACR decrease of at least 30% with no substantial fluid retention during the enrichment period (responders)were included in the double-blind treatment period. Responders were randomly assigned to receive either atrasentan 0·75 mg orally daily or placebo. All patients and investigators were masked to treatment assignment. The primary endpoint was a composite of doubling of serum creatinine (sustained for ≥30 days)or end-stage kidney disease (eGFR <15 mL/min per 1·73 m 2 sustained for ≥90 days, chronic dialysis for ≥90 days, kidney transplantation, or death from kidney failure)in the intention-to-treat population of all responders. Safety was assessed in all patients who received at least one dose of their assigned study treatment. The study is registered with ClinicalTrials.gov, number NCT01858532. Findings: Between May 17, 2013, and July 13, 2017, 11 087 patients were screened; 5117 entered the enrichment period, and 4711 completed the enrichment period. Of these, 2648 patients were responders and were randomly assigned to the atrasentan group (n=1325)or placebo group (n=1323). Median follow-up was 2·2 years (IQR 1·4–2·9). 79 (6·0%)of 1325 patients in the atrasentan group and 105 (7·9%)of 1323 in the placebo group had a primary composite renal endpoint event (hazard ratio [HR]0·65 [95% CI 0·49–0·88]; p=0·0047). Fluid retention and anaemia adverse events, which have been previously attributed to endothelin receptor antagonists, were more frequent in the atrasentan group than in the placebo group. Hospital admission for heart failure occurred in 47 (3·5%)of 1325 patients in the atrasentan group and 34 (2·6%)of 1323 patients in the placebo group (HR 1·33 [95% CI 0·85–2·07]; p=0·208). 58 (4·4%)patients in the atrasentan group and 52 (3·9%)in the placebo group died (HR 1·09 [95% CI 0·75–1·59]; p=0·65). Interpretation: Atrasentan reduced the risk of renal events in patients with diabetes and chronic kidney disease who were selected to optimise efficacy and safety. These data support a potential role for selective endothelin receptor antagonists in protecting renal function in patients with type 2 diabetes at high risk of developing end-stage kidney disease. Funding: AbbVie
CARB-ES-19 Multicenter Study of Carbapenemase-Producing Klebsiella pneumoniae and Escherichia coli From All Spanish Provinces Reveals Interregional Spread of High-Risk Clones Such as ST307/OXA-48 and ST512/KPC-3
ObjectivesCARB-ES-19 is a comprehensive, multicenter, nationwide study integrating whole-genome sequencing (WGS) in the surveillance of carbapenemase-producing K. pneumoniae (CP-Kpn) and E. coli (CP-Eco) to determine their incidence, geographical distribution, phylogeny, and resistance mechanisms in Spain.MethodsIn total, 71 hospitals, representing all 50 Spanish provinces, collected the first 10 isolates per hospital (February to May 2019); CPE isolates were first identified according to EUCAST (meropenem MIC > 0.12 mg/L with immunochromatography, colorimetric tests, carbapenem inactivation, or carbapenem hydrolysis with MALDI-TOF). Prevalence and incidence were calculated according to population denominators. Antibiotic susceptibility testing was performed using the microdilution method (EUCAST). All 403 isolates collected were sequenced for high-resolution single-nucleotide polymorphism (SNP) typing, core genome multilocus sequence typing (cgMLST), and resistome analysis.ResultsIn total, 377 (93.5%) CP-Kpn and 26 (6.5%) CP-Eco isolates were collected from 62 (87.3%) hospitals in 46 (92%) provinces. CP-Kpn was more prevalent in the blood (5.8%, 50/853) than in the urine (1.4%, 201/14,464). The cumulative incidence for both CP-Kpn and CP-Eco was 0.05 per 100 admitted patients. The main carbapenemase genes identified in CP-Kpn were blaOXA–48 (263/377), blaKPC–3 (62/377), blaVIM–1 (28/377), and blaNDM–1 (12/377). All isolates were susceptible to at least two antibiotics. Interregional dissemination of eight high-risk CP-Kpn clones was detected, mainly ST307/OXA-48 (16.4%), ST11/OXA-48 (16.4%), and ST512-ST258/KPC (13.8%). ST512/KPC and ST15/OXA-48 were the most frequent bacteremia-causative clones. The average number of acquired resistance genes was higher in CP-Kpn (7.9) than in CP-Eco (5.5).ConclusionThis study serves as a first step toward WGS integration in the surveillance of carbapenemase-producing Enterobacterales in Spain. We detected important epidemiological changes, including increased CP-Kpn and CP-Eco prevalence and incidence compared to previous studies, wide interregional dissemination, and increased dissemination of high-risk clones, such as ST307/OXA-48 and ST512/KPC-3